Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients

This study is currently recruiting participants.

Verified by Stanford University, May 2008

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00568282

Purpose

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Condition	Intervention
Lung Cancer	Procedure: phlebotomy

MedlinePlus related topics: Cancer Lung Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)

Further study details as provided by Stanford University:

Estimated Enrollment:	100
Study Start Date:	February 2007

Detailed Description:

The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:Inclusion Criteria (Cases):

Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
ability to sign informed consent
at least 18 years of age

Inclusion Criteria (Controls):

no known prior or active malignancy
ability to sign informed consent
at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years

2. pregnant women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568282

Locations

United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Lisa Zhou, MD 650-736-4112 yaya@stanford.edu
Contact: Cancer Clinical Trials Office (650) 498-7061
Principal Investigator: Heather A. Wakelee

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Heather A. Wakelee

Stanford University

More Information

Study ID Numbers:	SU-11052007-804, 96710, LUN0017, NCT00568282
Study First Received:	December 4, 2007
Last Updated:	May 30, 2008
ClinicalTrials.gov Identifier:	NCT00568282
Health Authority:	United States: Food and Drug Administration; USA:Institutional Review Board

Study placed in the following topic categories:

Thoracic Neoplasms
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases

Additional relevant MeSH terms:

Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 15, 2009